Table 1 Characteristics of the included studies in this meta-analysis
Study | Year | Country | Cancer type | Total | Tumor stage | Method | Cutoff | VEGF expression | Survival analysis | Multivariate analysis | HR statistic | HR (95% CI) | Follow-up months | NOS score | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
High expression | High with LNM | Low expression | Low with LNM | ||||||||||||||
Byung [14] | 2006 | Korea | ICC | 79 | I–IV | RT-qPCR | Median | 36 | 7 | 21 | 3 | OS | Rep | SC | 2.02 (1.18–3.46) | 72 | 8 |
Liu [15] | 2010 | China | ICC | 86 | I–IV | RT-qPCR | Median | 69 | 27 | 11 | 1 | OS | NR | SC | 1.95 (0.73–5.16) | 140 | 7 |
Shinichi [16] | 2008 | Japan | ICC | 62 | I–IV | RT-qPCR | Mean | 88 | 19 | 62 | 19 | OS | Rep | SC | 1.74 (1.07–2.82) | 120 | 7 |
Wang [17] | 2009 | China | ICC | 130 | I–IV | RT-qPCR | Median | 69 | 27 | 11 | 1 | OS | NR | SC | 2.85 (1.08–7.56) | 140 | 8 |
Xiao [18] | 2012 | China | ICC | 60 | I–IV | RT-qPCR | Mean | 47 | 19 | 11 | 2 | OS | NR | SC | 1.66(0.71–3.90) | 60 | 7 |
Xu [19] | 2015 | China | ICC | 435 | I–IV | RT-qPCR | Mean | 65 | 13 | 27 | 2 | OS | Rep | SC | 3.003 (1.016–8.875) | 100 | 8 |
Zhu [20] | 2020 | China | ICC | 102 | I–IV | RT-qPCR | Median | 122 | 73 | 21 | 5 | OS | NR | SC | 1.82 (1.17–2.82) | 60 | 7 |